JAK2 and myeloproliferative neoplasm: Our results suggest that patients with MPN who present with ACS and have a history of JAK2 mutation, prior CVD, have recently been diagnosed with MPN, and have leukocytosis at the time of ACS should be monitored closely for adverse cardiac events.